These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

237 related items for PubMed ID: 15308384

  • 1. Dyslipidemia in type 2 diabetes.
    Krauss RM, Siri PW.
    Med Clin North Am; 2004 Jul; 88(4):897-909, x. PubMed ID: 15308384
    [Abstract] [Full Text] [Related]

  • 2. Pharmacologic treatment of type 2 diabetic dyslipidemia.
    Moon YS, Kashyap ML.
    Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
    [Abstract] [Full Text] [Related]

  • 3. Lipid-lowering effect of simvastatin in patients of type 2 diabetes mellitus.
    Udawat H, Goyal RK.
    Indian Heart J; 2001 Dec; 53(2):172-6. PubMed ID: 11428472
    [Abstract] [Full Text] [Related]

  • 4. Lipid abnormalities in insulin resistant states.
    Watson KE, Horowitz BN, Matson G.
    Rev Cardiovasc Med; 2003 Dec; 4(4):228-36. PubMed ID: 14668690
    [Abstract] [Full Text] [Related]

  • 5. [Dyslipidemia in diabetes mellitus].
    Niemeijer-Kanters SD, Banga JD, Erkelens DW.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):769-74. PubMed ID: 11346913
    [Abstract] [Full Text] [Related]

  • 6. Statins and diabetes.
    Carmena R, Betteridge DJ.
    Semin Vasc Med; 2004 Nov 21; 4(4):321-32. PubMed ID: 15861314
    [Abstract] [Full Text] [Related]

  • 7. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2].
    Wolffenbuttel BH, Huijberts MS.
    Ned Tijdschr Geneeskd; 2001 Apr 21; 145(16):761-5. PubMed ID: 11346911
    [Abstract] [Full Text] [Related]

  • 8. Management of dyslipidemia in diabetes.
    Solano MP, Goldberg RB.
    Cardiol Rev; 2006 Apr 21; 14(3):125-35. PubMed ID: 16628021
    [Abstract] [Full Text] [Related]

  • 9. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
    Staels B, Maes M, Zambon A.
    Nat Clin Pract Cardiovasc Med; 2008 Sep 21; 5(9):542-53. PubMed ID: 18628776
    [Abstract] [Full Text] [Related]

  • 10. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR).
    Gudbjörnsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM, Swedish National Diabetes Register (NDR).
    Diabet Med; 2009 Jan 21; 26(1):53-60. PubMed ID: 19125761
    [Abstract] [Full Text] [Related]

  • 11. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH.
    Am J Cardiol; 2008 Dec 22; 102(12A):41L-47L. PubMed ID: 19084089
    [Abstract] [Full Text] [Related]

  • 12. Strategies in ongoing clinical trials to reduce cardiovascular disease in patients with diabetes mellitus and insulin resistance.
    Mazzone T.
    Am J Cardiol; 2004 Jun 03; 93(11A):27C-31C. PubMed ID: 15178514
    [Abstract] [Full Text] [Related]

  • 13. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G, Cicero AE, Bertone G, Piccinni MN, Ciccarelli L, Roggeri DE.
    Clin Ther; 2004 Oct 03; 26(10):1599-607. PubMed ID: 15598476
    [Abstract] [Full Text] [Related]

  • 14. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
    May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.
    Am J Cardiol; 2008 Feb 15; 101(4):486-9. PubMed ID: 18312763
    [Abstract] [Full Text] [Related]

  • 15. Mixed dyslipidemia among patients using lipid-lowering therapy in French general practice: an observational study.
    Van Ganse E, Laforest L, Burke T, Phatak H, Souchet T.
    Clin Ther; 2007 Aug 15; 29(8):1671-81. PubMed ID: 17919548
    [Abstract] [Full Text] [Related]

  • 16. Lipids in type 2 diabetes.
    Laakso M.
    Semin Vasc Med; 2002 Feb 15; 2(1):59-66. PubMed ID: 16222596
    [Abstract] [Full Text] [Related]

  • 17. Diabetic dyslipidemia: a case for aggressive intervention in the absence of clinical trial and cost effectiveness data.
    Lewis GF.
    Can J Cardiol; 1995 May 15; 11 Suppl C():24C-28C. PubMed ID: 7750045
    [Abstract] [Full Text] [Related]

  • 18. Management of diabetic dyslipidemia.
    Del Pilar Solano M, Goldberg RB.
    Endocrinol Metab Clin North Am; 2005 Mar 15; 34(1):1-25, v. PubMed ID: 15752919
    [Abstract] [Full Text] [Related]

  • 19. Intensive insulin therapy reduces small dense low-density lipoprotein particles in patients with type 2 diabetes mellitus: relationship to triglyceride-rich lipoprotein subspecies.
    Hayashi T, Hirano T, Yamamoto T, Ito Y, Adachi M.
    Metabolism; 2006 Jul 15; 55(7):879-84. PubMed ID: 16784958
    [Abstract] [Full Text] [Related]

  • 20. Longitudinal lipid screening and use of lipid-lowering medications in pediatric type 1 diabetes.
    Maahs DM, Wadwa RP, McFann K, Nadeau K, Williams MR, Eckel RH, Klingensmith GJ.
    J Pediatr; 2007 Feb 15; 150(2):146-50, 150.e1-2. PubMed ID: 17236891
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.